Then, to assess the efficacy of HIF2α-CD27 PAMs, we tested micelle binding to human patient tissue-derived ccRCC cells in vitro and evaluated their ability to inhibit cancer cell glucose transport, proliferation, release of angiogenic factors, and migration. The gene discussed is EPAS1; the disease is cancer.